Dave Stewart

Dave Stewart currently serves as a Research Scientist at Rapafusyn Pharmaceuticals since June 2022 and has held the position of Research Scientist I at GlycoMimetics since September 2015, where significant contributions were made to the development and qualification of flow cytometry reagents for clinical trials in acute myeloid leukemia. Prior experience includes over a decade at MedImmune in oncology research, where responsibilities encompassed planning and executing preclinical studies, along with leading receptor signaling projects. Additional roles at SAIC and Genetic Therapy, Inc. involved biodefense research and studies on oncolytic vectors, respectively. Education includes a BA/MS in Biology from the University of Maryland Baltimore County.